NASDAQ:PGEN Precigen (PGEN) Stock Price, News & Analysis $1.62 +0.02 (+0.93%) As of 07/3/2025 03:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Precigen Stock (NASDAQ:PGEN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Precigen alerts:Sign Up Key Stats Today's Range$1.58▼$1.6350-Day Range$1.28▼$1.6352-Week Range$0.65▼$2.17Volume611,400 shsAverage Volume1.42 million shsMarket Capitalization$479.67 millionP/E RatioN/ADividend YieldN/APrice Target$6.00Consensus RatingBuy Company Overview Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland. Read More Precigen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks74th Percentile Overall ScorePGEN MarketRank™: Precigen scored higher than 74% of companies evaluated by MarketBeat, and ranked 252nd out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingPrecigen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePrecigen has only been the subject of 2 research reports in the past 90 days.Read more about Precigen's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Precigen are expected to grow in the coming year, from ($0.32) to ($0.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Precigen is -2.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Precigen is -2.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrecigen has a P/B Ratio of 12.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Precigen's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.85% of the float of Precigen has been sold short.Short Interest Ratio / Days to CoverPrecigen has a short interest ratio ("days to cover") of 17.4, which indicates bearish sentiment.Change versus previous monthShort interest in Precigen has recently decreased by 1.27%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPrecigen does not currently pay a dividend.Dividend GrowthPrecigen does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.77 Percentage of Shares Shorted16.85% of the float of Precigen has been sold short.Short Interest Ratio / Days to CoverPrecigen has a short interest ratio ("days to cover") of 17.4, which indicates bearish sentiment.Change versus previous monthShort interest in Precigen has recently decreased by 1.27%, indicating that investor sentiment is improving. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 3 news articles for Precigen this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for PGEN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows5 people have added Precigen to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Precigen insiders have not sold or bought any company stock.Percentage Held by Insiders47.10% of the stock of Precigen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 33.51% of the stock of Precigen is held by institutions.Read more about Precigen's insider trading history. Receive PGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Precigen and its competitors with MarketBeat's FREE daily newsletter. Email Address PGEN Stock News HeadlinesPrecigen, Inc. (PGEN) Latest Stock News & Headlines - Yahoo FinanceJuly 3 at 9:41 PM | finance.yahoo.comPrecigen Announces Key Approvals at Annual MeetingJuly 2 at 8:14 PM | theglobeandmail.comIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd.July 5 at 2:00 AM | Brownstone Research (Ad)Precigen, Inc.'s (NASDAQ:PGEN) market cap touched US$455m last week, benefiting both private equity firms who own 33% as well as institutionsJune 12, 2025 | finance.yahoo.comJ.P. Morgan Sticks to Its Sell Rating for Precigen (PGEN)May 20, 2025 | theglobeandmail.comPrecigen, Inc.: Precigen Reports First Quarter 2025 Financial Results and Business UpdatesMay 17, 2025 | finanznachrichten.deCantor Fitzgerald maintains Overweight on Precigen stockMay 17, 2025 | uk.investing.comPrecigen Reports First Quarter 2025 Financial Results and Business UpdatesMay 14, 2025 | prnewswire.comSee More Headlines PGEN Stock Analysis - Frequently Asked Questions How have PGEN shares performed this year? Precigen's stock was trading at $1.12 at the beginning of 2025. Since then, PGEN stock has increased by 45.1% and is now trading at $1.6250. How were Precigen's earnings last quarter? Precigen, Inc. (NASDAQ:PGEN) posted its quarterly earnings results on Wednesday, May, 14th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01. The biotechnology company earned $1.34 million during the quarter, compared to analyst estimates of $0.50 million. Precigen had a negative trailing twelve-month return on equity of 279.20% and a negative net margin of 3,728.87%. How do I buy shares of Precigen? Shares of PGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Precigen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Precigen investors own include Nordic American Tankers (NAT), ZIOPHARM Oncology (ZIOP), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Hess (HES) and Boeing (BA). Company Calendar Last Earnings5/14/2025Today7/05/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PGEN CIK1356090 Webwww.precigen.com Phone(301) 556-9900FaxN/AEmployees190Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$6.00 Low Stock Price Target$6.00 Potential Upside/Downside+269.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$126.24 million Net Margins-3,728.87% Pretax Margin-3,770.86% Return on Equity-279.20% Return on Assets-79.74% Debt Debt-to-Equity RatioN/A Current Ratio3.53 Quick Ratio3.53 Sales & Book Value Annual Sales$3.92 million Price / Sales122.36 Cash FlowN/A Price / Cash FlowN/A Book Value$0.13 per share Price / Book12.50Miscellaneous Outstanding Shares295,180,000Free Float156,150,000Market Cap$479.67 million OptionableOptionable Beta1.78 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:PGEN) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precigen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precigen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.